Nonsteroidal anti-inflammatory drug administration alters crypt distribution of the peroxisomal marker acyl-coenzyme A oxidase 1 in the equine right dorsal colon.

Overview

• This study investigates how nonsteroidal anti-inflammatory drugs (NSAIDs) affect the distribution of peroxisomal markers—specifically acyl-coenzyme A oxidase 1 (ACOX1) and peroxisomal biogenesis factor 14 (PEX14)—in different regions of the horse colon, focusing on the right dorsal colon (RDC) and left ventral colon (LVC).
• The research identifies that NSAID treatment alters ACOX1 levels specifically at the crypt tips of the RDC but not in other areas, suggesting a localized tissue response that might relate to NSAID-induced colon injury.

Background and Purpose

• Peroxisomes are cellular organelles involved in lipid metabolism and reactive oxygen species detoxification, and their dysfunction can contribute to tissue injury.
• The equine colon is divided into regions with differing anatomy and susceptibility to injury, notably the right dorsal colon (RDC), which is often more vulnerable.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used but can cause gastrointestinal side effects, including damage to the colon.
• The study aimed to characterize the distribution of peroxisomal markers ACOX1 and PEX14 within different crypt regions (tip, mid, base) of the RDC and LVC in healthy versus NSAID-treated horses.

Methods

• Tissue samples from archived colonic specimens were obtained from 10 horses divided into two groups: 5 treated with phenylbutazone (an NSAID) and 5 given placebo, both administered orally twice daily for 10 days before euthanasia.
• Samples were taken from two colonic regions: the right dorsal colon (RDC) and the left ventral colon (LVC).
• Immunofluorescence staining was used to detect and localize the peroxisomal markers PEX14 (indicative of peroxisomal biogenesis) and ACOX1 (an enzyme involved in peroxisomal fatty acid oxidation).
• The fluorescence area per cell for each marker was quantitatively measured along different portions of the crypt axis: tip, mid, and base.
• Comparisons were made between regions (RDC vs. LVC), crypt locations (tip, mid, base), and treatment groups (NSAID vs placebo/control).

Results

• In control horses (placebo group), there was no significant difference in PEX14 or ACOX1 distribution between the RDC and LVC regions.
• Within the crypts of both regions in control horses, ACOX1 fluorescence area per cell was higher at the crypt tip compared to the crypt base, indicating more ACOX1 enzyme localized toward the upper portion of the crypt.
• PEX14 distribution did not vary significantly along the crypt axis in either region, suggesting that peroxisomal biogenesis is fairly uniform within the crypt.
• NSAID administration did not produce significant changes in PEX14 distribution in either colon region.
• However, NSAID-treated horses showed a significantly higher ACOX1 fluorescence area per cell at the crypt tip in the RDC compared to the LVC, with a mean difference of 1.66 μm² per nucleus (confidence interval 0.35 to 2.97), indicating a region-specific increase in this peroxisomal enzyme.

Interpretation and Significance

• The uniform distribution of PEX14 in all groups suggests that NSAID treatment does not affect peroxisomal biogenesis directly in these tissues.
• The increased ACOX1 at the crypt tip in the RDC in NSAID-treated horses implies a heightened metabolic or oxidative response localized to this region, possibly as a reaction to NSAID-induced stress or damage.
• The crypt tip localization may indicate where peroxisomal fatty acid oxidation activity is most affected and potentially linked to ongoing cellular responses or injury processes.
• The RDC’s distinct response might explain its greater susceptibility to NSAID-induced injury observed clinically, potentially due to altered peroxisomal function.
• These findings highlight the importance of region-specific peroxisomal pathways in maintaining colonic health and suggest avenues for further research into mechanisms of NSAID toxicity and protective strategies.

Conclusions and Future Directions

• Peroxisomal marker distribution in healthy horse colon tissue does not differ significantly by region, but NSAID treatment induces localized changes in ACOX1 expression in the RDC.
• Region-specific alterations in peroxisomal enzyme activity could contribute to the vulnerability of the RDC to NSAID-induced damage.
• Further studies are warranted to explore the molecular mechanisms underlying these changes and to develop interventions that might mitigate NSAID-associated colonic injury in horses.